Demand for off-site blood collection is climbing on every front. Hospital-at-home programs, Medicare Advantage in-home assessments, employer wellness draws, clinical trial home visits, skilled nursing facility (SNF) routes, and concierge laboratory services are all pushing more specimens out of fixed draw stations and into living rooms, conference rooms, and parked vans. The Centers for Medicare & Medicaid Services (CMS) Acute Hospital Care at Home waiver, extended again in recent reauthorizations, has made the model permanent enough for serious capital investment.

A mislabeled tube is not a paperwork mistake. It is a direct line to the wrong transfusion, the wrong diagnosis, a delayed treatment, or a sentinel event. The College of American Pathologists (CAP) Q-Tracks studies have consistently shown specimen identification errors affecting roughly 1 in every 1,000 specimens across participating laboratories—a rate that sounds small until you multiply it across the millions of tubes drawn every day.

Hemolysis—the breakdown of red blood cells that releases intracellular contents into serum or plasma—is the leading cause of specimen rejection in clinical laboratories. Studies consistently put hemolysis-related rejection rates between 40% and 70% of all preanalytical errors, translating to redraws, delayed results, increased sharps waste, and patient dissatisfaction. For a mid-size hospital running 500 blood draws per day, even a 5% hemolysis rate means 25 redraws daily—thousands of unnecessary needle sticks and lab hours annually.